Please login to the form below

Not currently logged in
Email:
Password:

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

With operating conditions increasingly tough for its core diabetes franchise as well, Novo has been trying to grow its pipeline, but an attempt to buy Ablynx and its lead product caplacizumab

Latest news

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Both deals boost its positions in rare diseases and haematology, with Ablynx’lead product caplacizumab acquired thrombotic thrombocytopenic purpura (aTTP) slotting neatly into Sanofi’s pipeline along with the Bioverativ haemophilia ... Geel.

  • Ablynx knocks-back Novo Nordisk’s second bid Ablynx knocks-back Novo Nordisk’s second bid

    Ablynx has rejected Novo Nordisk’s proposal to acquire the Belgian biopharma and its lead candidate caplacizumab, stating that the deal wouldn’t be in the “best interests of the company”. ... However Ablynx - whose long-term plan is to become a

  • Novo Nordisk makes improved €2.6bn offer for Ablynx Novo Nordisk makes improved €2.6bn offer for Ablynx

    Danish pharmaceutical company Novo Nordisk is hoping to bolster its haematology franchise after stating interest in Ablynx along with its lead asset caplacizumab - a rare bleeding disorder treatment. ... and global commercialisation of caplacizumab for

  • Belgium's Ablynx enters the US market Belgium's Ablynx enters the US market

    One of his priorities will be to lead the commercialisation of Ablynx’s orphan drug caplacizumab. ... We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab.".

  • Ablynx buoyant as lead antibody aces phase III trial Ablynx buoyant as lead antibody aces phase III trial

    Ablynx buoyant as lead antibody aces phase III trial. Caplacizumab met its primary endpoint and reduced aTTP-related death by 74%. ... Belgian biotech Ablynx has chalked up a big win with its lead candidate caplacizumab for a rare blood disorder,

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Strategically caplacizumab represented a good fit for Novo Nordisk as it complements the company's portfolio of products focused on haemophilia. ... Acquisition company. 7, 000. Ablynx/Sanofi. Nanobody platform product pipeline; lead product caplacizumab

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics